ABSTRACT
INTRODUCTION
The acute respiratory distress syndrome (ARDS) is characterised by diffuse alveolar injury and immune cell infiltration, resulting in intractable hypoxemia [1] . Despite the adoption of lung-protective ventilation, mortality remains high [2] , and many survivors suffer long-term physical or neurocognitive sequelae, with fewer than 50% returning to work [2] .
Management remains largely supportive with optimisation of ventilator parameters [3] , judicious fluid balance, and treatment of underlying causes; no pharmacological interventions have proven beneficial.
Accumulation of neutrophils (PMNs) in the lung microvasculature, interstitial and alveolar compartments is a key feature of ARDS [4] , and association has been reported between intensity of alveolar neutrophil infiltration and disease severity [5] . Inappropriate accumulation/activation of PMNs within the alveoli is proposed to cause unrestrained release of oxygen radicals, proteases and neutrophil extracellular traps (NETs). Due to challenges inherent in isolating alveolar PMNs ( alv PMNs), their functional activity in ARDS is largely unknown. Historically, mouse models have been used as surrogates for alv PMNs [6] ;
however, rodent neutrophils differ markedly from their human counterparts.
Traditionally PMNs have been viewed as a homogenous population of short-lived cells with limited transcriptional capacity and a fixed functional repertoire. More recently, concepts of long-lived PMNs, retrograde trans-endothelial migration and PMN plasticity have emerged [7] [8] [9] [10] [11] [12] . Given recent demonstrations that PMNs can modify their transcriptional profile following an inflammatory insult [13] , genome-wide transcriptional analysis provides a powerful tool to identify novel targets relevant to altered PMN functions, and has been successfully applied in asthma, pulmonary arterial hypertension and ARDS [14] ; however, studies in ARDS are based on the analysis of total peripheral white blood cells rather than purified neutrophils.
Lung epithelial cells [15] synthesize granulocyte macrophage-colony stimulating factor (GM-CSF), a cytokine essential for alveolar macrophage function [16] [17] and surfactant homeostasis [18] [19] . Conversely, during inflammation GM-CSF potentiates superoxideanion production [20] , promotes PMN survival [21] , and is detrimental in models of acute lung injury [22] . PMN longevity increases dramatically in ARDS, and some studies have identified GM-CSF as a major pro-survival mediator [23] . Whilst the molecular mechanisms governing PMN lifespan in ARDS are incompletely understood, the cytoprotective effect of GM-CSF in PMNs in vitro is Class 1 phosphoinositide 3-kinase (PI3K)-dependent [21] .
PI3K inhibition prevents lung tissue edema and leukocyte recruitment in models of ARDS [24] , and inhibition of PI3Kγ in a sepsis model reduces end-organ damage [25] . Following the early exuberant pro-inflammatory response in ARDS, patients develop immune-paresis, increasing susceptibility to nosocomial infections [26] ; recent studies demonstrate that inhibition of PI3Kδ may improve PMN responses during this phase [27] . These observations have triggered considerable interest in the therapeutic use of PI3K inhibitors in ARDS.
Herein we present the first comprehensive characterization of purified ARDS blood [28] .
MATERIALS and METHODS

Ethics
All studies complied with the Declaration of Helsinki. Written informed consent was obtained from the legal surrogate of ARDS patients (UK08/H0306/17). Paired blood samples were obtained simultaneously from age and gender matched healthy volunteers (HV) (UK06/Q0108/281).
Bronchoalveolar lavage
Patients fulfilling the Berlin criteria for ARDS [29] were recruited from mixed medical/surgical and neurosciences/trauma intensive care units in a UK teaching hospital; exclusion criteria were age <18 years, HIV positive, or if informed assent could not be obtained. [30] to >90% purity and >98% viability.
blood PMNs were purified over discontinuous plasma-Percoll gradients [28] .
PMN morphology
PMN were classified by nuclear morphology, with the assessor blinded to sample origin.
Mature PMN displayed 3-4 nuclear lobes connected by heterochromatin filaments. Band
PMNs had less condensed chromatin and incompletely segmented nuclei [31] , whilst hypersegmented PMNs possessed ≥5 lobes.
PMN activation and apoptosis
HV and ARDS blood PMNs and unprocessed BALF were re-suspended in PBS containing 5%
BSA and protease inhibitor cocktail (Complete Mini EDTA-free, Roche). Samples were stained with CD62L-APC (BD Pharmingen-clone 559772), CD11b-FITC (Beckman Coulter clone IM0530) or isotype-matched controls. PMN apoptosis was assessed after 20 hours by flow cytometry using FITC-labelled Annexin-V/propidium iodide (AnV/PI, BDPharmingen).
PMN oxidative burst
Neutrophils (5x10 6 /mL) were primed with tumor necrosis factor (TNF)-α (R&D Systems), GM-CSF, control BALF or ARDS BALF at 37°C for 30 minutes. The oxidative burst in response to fMLP (100 nM), zymosan or heat-killed Streptococcus pneumoniae (serumopsonized, 5-7 particles/PMN) was assessed by luminol-dependent chemiluminescence [30] .
Quantification of inflammatory mediators
BALF and serum mediators were measured by ELISA (LPS (Kamiya), survivin and LTB 4 (R&D Systems)), or using the Human Biomarker 40-Plex V-PLEX Kit and Human MMP 3-Plex Ultra-Sensitive Kit (MesoScale Discovery). Where stated BALF samples were corrected to the total protein concentration (Pierce™ BCA-Protein Assay).
PMN phagocytosis
PMN phagocytic capacity was assessed using 1 mg/ml pHrodo™ RED Staphylococcus aureus Bioparticles ® (Life Technologies). Internalization was verified by live confocal imaging.
NET formation
blood PMNs and alv PMNs (1x10 6 /ml) incubated with Sytox Green (5 µM, Life Technologies)
were seeded onto 96 well optical microplates (BD Biosciences). NET formation was quantitated by hourly fluorescence measurements and verified by fluorescence microscopy using rabbit anti-histone H3 (Ab5103, Abcam).
Neutrophil cytoskeletal remodelling
Freshly isolated PMNs (1 x10 6 /ml) were fixed (4% PFA), permeabilized (0.5% Triton) and stained with anti-neutrophil elastase (Santa Cruz, 1:1,000) and rhodamine phalloidin 1:200 (Invitrogen). 
Genome-wide transcriptomic changes
Statistical analysis
For each dataset analysed an appropriate linear mixed model was fitted. When required the data were logarithmically transformed to meet the assumptions of the analysis i.e. normally distributed errors and homogeneity of variance. Correction for false discovery rates in the transcriptional and cytokine analysis was according to the method of Benjamini and
Hochberg [33] . The analyses were conducted in SAS version 9.3. Results are presented as means ± SEM of (n) independent experiments, with p<0.05 considered statistically significant. Full details of the number of patients and HVs included in each assay are provided in Suppl Figure S1 .
RESULTS
ARDS patient characteristics
Twenty-three mechanically ventilated patients fulfilling the 2011 Berlin definition for ARDS were recruited; their clinical, demographic and physiological characteristics are outlined in Table 1 Table 1) . PMN abundance in BALF did not correlate with initial ARDS severity, abnormalities in gas exchange or BALF protein concentration (data not shown).
ARDS PMNs are phenotypically distinct
Comparing purified HV blood PMNs, ARDS blood PMNs and alv PMNs revealed striking differences in cell morphology. While HV blood PMNs had few hyper-segmented PMNs, alv ARDS PMNs displayed abundant hyper-segmented nuclei and cytoplasmic vacuolation ( Figure 1A) ; hyper-segmented PMNs were not identified in control BALF. Immature 'band'
PMNs were also more common in ARDS blood PMNs and alv PMNs ( Figure 1A ). 
ARDS blood and alveolar PMNs have preserved capacity for phagocytosis and NET formation
Previous investigators have identified a defect in the phagocytic and microbicidal activity of neutrophils from ARDS patients [38] . However, in our cohort, flow cytometry and confocal microscopy demonstrated that the capacity of ARDS alv PMNs and blood PMNs to phagocytose pHrodo™ RED-labelled Staphylococcus aureus was fully preserved (Figure 3A-B) . This assay, supported by live cell imaging, is based on differential fluorescence of this bioparticle in an acidic environment, ensuring that only organisms within functional phagosomes are detected.
In addition to phagocytosis and the oxidative burst, PMNs deploy NETs to facilitate pathogen clearance. NETs are composed principally of a DNA scaffold decorated with anti-microbial granule proteins, which acts as a mesh to immobilize pathogens ( Figure 3C ). In response to PMA (Figure 3 C-D 
Defining the impact of ARDS on serum/BALF cytokine profiles and the transcriptional signatures of blood PMNs
To address whether factors present in the serum or BALF in ARDS patients could account for the primed/pro-survival PMN phenotype, a series of multiplex ELISA and bioassays were used to characterize the cytokine and growth factor profiles (n=18). As shown in Figure 4 and Suppl Figure S2 , a consistent profile of raised acute phase markers (e.g. CRP, SAA) and inflammatory cytokines (e.g. TNFα, TARC, MCP-1, IL-8 and IL-6) was observed in ARDS serum and BALF compared to HV samples. By contrast, when BALF samples were corrected for total protein concentration, only CRP, IL-6 and MCP-1 levels were significantly higher in ARDS compared to control (Suppl Figure S2) . Of note, at the single time point sampled, GM-CSF was only quantifiable in 5/23 ARDS BALF samples (LLoQ 7.6 pg/ml).
RNA transcriptomic analysis comparing freshly isolated ARDS blood PMNs with HV blood PMNs revealed a total of 1319 altered genes (using cut-offs of fold-change >1.5 and p<0.05; top ranked up-and down-regulated transcripts shown in Figure 5A ; full list of all 1319 genes and their relative fold changes in Suppl Table S3 ). Using NextBio (which recognised 1282 of the 1319 differentially expressed genes) we compared these changes to publically available datasets, revealing a striking similarity to data in leukocytes from patients with severe burns or sepsis [39] [40] ; not only was there a strong overlap in gene changes, but also the direction of change correlated almost completely ( Figure 5B ).
Ingenuity analysis revealed a significant increase in pathways associated with the immune response, cytoskeletal remodelling and mucin production, as well as significant decreases in cell death/apoptosis pathways, consistent with the neutrophil phenotype observed (Suppl 
Potential role of PI3K inhibition as a strategy to modulate ARDS blood/alv PMN behaviour
A key objective of this study was to define the sensitivity of inflammatory PMNs to PI3K inhibition, since this pathway is pivotal in neutrophil survival, priming/activation and reactive oxygen species (ROS) production [30] . Firstly, we confirmed that a pan-PI3K inhibitor ZSTK474 (10 µM) [41] , and to a lesser extent the p38MAPK inhibitor SB741445 (10 µM)
blocked GM-CSF-induced PMN survival in HV blood PMNs in vitro ( Figure 7A ). ZSTK474 also blocked the survival effect of ARDS BALF supernatant on HV blood PMNs ( Figure 7B ).
However, neither compound restored normal neutrophil apoptosis in ARDS blood PMNs ( Figure 7C ) implying that the aberrant disease-associated neutrophil survival is either irreversible or operates through a PI3K-independent pathway. Given that even the delayed addition of ZSTK474 to GM-CSF-treated HV blood PMNs retains effectiveness in overcoming the pro-survival effect of this cytokine (data not shown), the involvement of a PI3K-independent pathway seems most likely. This conclusion is supported by the minimal overlap we observed between the transcriptomal signatures seen in the ARDS blood PMNs and those seen in HV blood PMNs treated with ZSTK474 (Suppl Figure S5) . In contrast, ROS production by PMNs from HV and ARDS patients was completely abrogated by ZSTK474
( Figure 7D ).
DISCUSSION
Isoform-selective PI3K inhibitors have been proposed as anti-inflammatory agents in diseases such as ARDS [42] , hence it is of importance to study their efficacy in patient-derived cells. [43] [44] ; these latter cells were immunosuppressive, inhibiting T cell proliferation by release of hydrogen peroxide at the neutrophil/T cell interface. Increased nuclear segmentation and oxidative potential has also been observed in tumor-associated neutrophils (45), associated with increased anti-tumor activity. Prolonged survival of ARDS alv PMNs has been reported previously and attributed to GM-CSF/G-CSF in BALF [23] , but in contrast to Matute-Bello et al we did not observe significantly elevated levels of these cytokines, perhaps related to disease heterogeneity and differences in sampling time. Delayed apoptosis has been measured in neutrophils recruited to skin chambers versus paired circulating neutrophils, but synovial fluid-derived PMNs from patients with rheumatoid arthritis exhibited normal apoptosis [46] . These differences correlated with local IL1-β levels, but IL1-β in our ARDS BALF fluid was not significantly elevated. The variable functional capacity of neutrophils from different locations underscores the need to explore the efficacy of potential therapeutic agents in disease-relevant cell populations.
We observed a pro-inflammatory cytokine profile in the blood of ARDS patients, including several established priming agents. In our study, ARDS blood and ARDS alv PMNs were functionally primed, and such cells have been implicated in lung injury [47] [48] . We previously demonstrated that the pulmonary capillary bed can trap and 'de-prime' neutrophils, and that this mechanism may fail in ARDS, augmenting the circulating pool of these potentially injurious cells [49] . Additional priming signals may be imparted during vascular transmigration [50] , and ARDS BALF also primed the oxidative burst of HV blood PMNs.
Thus a number of different factors may contribute to the pooling of primed neutrophils within the alveolar environment in ARDS. We further interrogated the activation state of ARDS blood PMNs by undertaking the first reported transcriptomic analysis of purified peripheral blood PMNs from ARDS patients.
ARDS
Our data revealed remarkable overlap between the transcriptomic profile of ARDS blood PMNs and those published for mixed leukocytes in burns (see Figure 4B ) and sepsis cohorts [34] [35] . The top five canonical pathways identified in the ARDS blood neutrophil gene signature were the glucocorticoid, IL-4, p38 MAPK, antigen presentation and CDC52 pathways. These were also within the top five pathways identified in the previous burns and sepsis cohorts using mixed leukocytes [39] [40] . This suggests that despite their heterogeneity, there is a strong commonalty in a range of acute severe inflammatory disorders. This also provides possible directions for novel therapeutic interventions aimed for example at the IL-4 receptor or p38 pathways.
In this study we sought to characterise the functional and transcriptional profile of PMNs isolated from ARDS patients' blood and airways. Although our study captured only 23
patients at a single time point, our data add considerably to knowledge of alv PMN and blood PMN function and signaling profiles in ARDS; they challenge data from both animal models and from healthy cells, with a marked primed and pro-survival phenotype, the latter recalcitrant to PI3K inhibition. We conclude that intervention with a PI3K inhibitor in these patients is unlikely to be an effective therapeutic strategy, since it will impair PMN bactericidal function without facilitating inflammation resolution. Our findings highlight the importance of working with patient-derived cells, particularly for biomedical research into novel treatments for ARDS. Table 1 Clinical characteristics of patients with ARDS for 30 minutes at 37 o C prior to stimulation with fMLP (100 nM). Chemiluminescence was recorded using a Centro LB 960 luminometer and expressed graphically as the absolute peak height in relative light units (RLU). Data were analysed on the log 10 scale using a linear mixed effects model with the HV donor fitted as a random effect (* P<0.05, ***P<0.0001). 
FIGURE LEGENDS
Online Data Supplement
Supplementary Figure 1 Flowchart showing the precise details of the number of subjects included in each assay.
Supplementary Figure 2 Inflammatory markers in the BALF of patients with ARDS
The concentration of key inflammatory mediators, were measured in control (n = 10) and ARDS (n = 18) BALF supernatants either by ELISA kit or an electrochemical luminescence immunoassay MesoScale Discovery (MSD) multiplex. S1(i) shows a heatmap representation of BALF markers in control subjects (C01-C10) vs ARDS patients (A01-18) without correction for BALF total protein, and S1(ii) shows a heatmap representation of the identical samples after correction for BALF total protein content (* P<0.05, ** P<0.01, ***P<0.001). 
Supplementary
Supplementary Table 2
Tables (i)-(vi) provide the full data set for blood and BALF cytokine values for HVs and ARDS patients. For the BALF samples these are given both corrected and uncorrected for total protein content.
Supplementary Table 3
A comprehensive list of all 1319 significantly altered genes (fold change > 1.5; unadjusted pvalue < 0.05; false discovery rate q-value < 0.05) identified by the comparison of freshly isolated ARDS blood PMNs with HV blood PMNs using Affymetrix mRNA transcriptomic analysis. C. D.
